<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Deep Pathomic Learning Defines Prognostic Subtypes and Molecular Drivers in Colorectal Cancer - Health AI Hub</title>
    <meta name="description" content="This paper introduces TDAM-CRC, a novel multiple instance learning model utilizing histopathological whole-slide images to significantly improve prognostic stra">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Deep Pathomic Learning Defines Prognostic Subtypes and Molecular Drivers in Colorectal Cancer</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.15067v1" target="_blank">2511.15067v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-19
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Zisong Wang, Xuanyu Wang, Hang Chen, Haizhou Wang, Yuxin Chen, Yihang Xu, Yunhe Yuan, Lihuan Luo, Xitong Ling, Xiaoping Liu
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI, cs.CV, q-bio.GN
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.15067v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.15067v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces TDAM-CRC, a novel multiple instance learning model utilizing histopathological whole-slide images to significantly improve prognostic stratification in colorectal cancer (CRC), outperforming conventional clinical staging and state-of-the-art models. It further integrates multi-omics data to uncover underlying molecular mechanisms, identifying metabolic reprogramming and an immunosuppressive tumor microenvironment in high-risk subtypes, and validating MRPL37 as a key prognostic biomarker.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research significantly advances personalized medicine for colorectal cancer by providing a more precise prognostic tool than current standards. It offers clinicians better risk stratification for treatment planning and identifies new molecular targets that could lead to novel therapeutic strategies.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper describes an AI-driven pathological model (TDAM-CRC) that utilizes deep multiple instance learning on histopathological whole-slide images to accurately predict patient prognosis and stratify risk in colorectal cancer. This AI application enhances clinical decision-making, facilitates personalized medicine, and aids in the discovery of novel molecular targets and biomarkers for improved patient management.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>The conventional TNM staging system is inadequate for personalized prognostic stratification of highly heterogeneous colorectal cancer (CRC).</li>
                    
                    <li>A novel deep learning model, TDAM-CRC (Tensor Decomposition Attention Multiple Instance Learning for Colorectal Cancer), was developed using histopathological whole-slide images (WSIs) for accurate prognostic prediction.</li>
                    
                    <li>The model was trained on the TCGA cohort (n=581) and robustly validated in an independent external cohort (n=1031), demonstrating significantly superior predictive performance compared to clinical staging and other state-of-the-art models.</li>
                    
                    <li>TDAM-CRC's risk score was confirmed as an independent prognostic factor in multivariable analysis.</li>
                    
                    <li>Multi-omics analysis revealed that the high-risk subtype identified by TDAM-CRC is closely associated with metabolic reprogramming and an immunosuppressive tumor microenvironment.</li>
                    
                    <li>Mitochondrial Ribosomal Protein L37 (MRPL37) was identified through interaction network analysis and validated as a key hub gene; its high expression, driven by promoter hypomethylation, serves as an independent biomarker for *favorable* prognosis.</li>
                    
                    <li>A clinical nomogram, integrating the TDAM-CRC risk score and traditional clinical factors, was constructed to provide a precise and interpretable decision-making tool for CRC patient management.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved developing TDAM-CRC, a multiple instance learning (MIL) model, trained on histopathological whole-slide images (WSIs) from the TCGA discovery cohort (n=581) and validated on an independent external cohort (n=1031). Multi-omics data (implicitly genomics, transcriptomics, epigenomics through 'promoter hypomethylation') were integrated to interpret deep pathomic features. Interaction network analysis was used to identify key molecular drivers. Prognostic performance was evaluated against conventional staging and state-of-the-art models, and the TDAM-CRC risk score was assessed as an independent prognostic factor via multivariable analysis. Finally, a nomogram was constructed by combining the TDAM-CRC risk score with clinical factors.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The TDAM-CRC model achieved robust and superior risk stratification for CRC patients, outperforming existing methods. The high-risk subtype predicted by the model showed strong associations with metabolic reprogramming and an immunosuppressive tumor microenvironment. MRPL37 was identified as a critical hub gene, and its high expression, driven by promoter hypomethylation, was validated as an independent biomarker for a favorable prognosis. A clinically applicable nomogram was successfully developed.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The TDAM-CRC model offers a robust, AI-driven tool for significantly improved personalized prognostic assessment in CRC, aiding in more tailored treatment decisions (e.g., adjuvant therapy intensity, surveillance). The identified molecular drivers (metabolic reprogramming, immunosuppression) and the biomarker MRPL37 provide potential targets for future therapeutic development, while the nomogram offers an interpretable and precise clinical decision-making aid.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the study. However, common limitations for AI models in medicine could include generalizability to diverse populations or specific clinical settings not represented in the validation cohorts, and the need for prospective validation.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The research facilitates personalized clinical decision-making and reveals new molecular targets, suggesting future work could involve prospective clinical trials to further validate the nomogram's utility, deeper mechanistic studies into MRPL37's role and its therapeutic potential, and exploring interventions targeting metabolic reprogramming or the immunosuppressive tumor microenvironment in high-risk CRC patients.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pathology</span>
                    
                    <span class="tag">Gastroenterology</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                    <span class="tag">Bioinformatics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Colorectal Cancer</span>
                    
                    <span class="tag tag-keyword">Prognosis</span>
                    
                    <span class="tag tag-keyword">Deep Learning</span>
                    
                    <span class="tag tag-keyword">Histopathology</span>
                    
                    <span class="tag tag-keyword">Multi-omics</span>
                    
                    <span class="tag tag-keyword">Biomarker</span>
                    
                    <span class="tag tag-keyword">MRPL37</span>
                    
                    <span class="tag tag-keyword">Nomogram</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Precise prognostic stratification of colorectal cancer (CRC) remains a major clinical challenge due to its high heterogeneity. The conventional TNM staging system is inadequate for personalized medicine. We aimed to develop and validate a novel multiple instance learning model TDAM-CRC using histopathological whole-slide images for accurate prognostic prediction and to uncover its underlying molecular mechanisms. We trained the model on the TCGA discovery cohort (n=581), validated it in an independent external cohort (n=1031), and further we integrated multi-omics data to improve model interpretability and identify novel prognostic biomarkers. The results demonstrated that the TDAM-CRC achieved robust risk stratification in both cohorts. Its predictive performance significantly outperformed the conventional clinical staging system and multiple state-of-the-art models. The TDAM-CRC risk score was confirmed as an independent prognostic factor in multivariable analysis. Multi-omics analysis revealed that the high-risk subtype is closely associated with metabolic reprogramming and an immunosuppressive tumor microenvironment. Through interaction network analysis, we identified and validated Mitochondrial Ribosomal Protein L37 (MRPL37) as a key hub gene linking deep pathomic features to clinical prognosis. We found that high expression of MRPL37, driven by promoter hypomethylation, serves as an independent biomarker of favorable prognosis. Finally, we constructed a nomogram incorporating the TDAM-CRC risk score and clinical factors to provide a precise and interpretable clinical decision-making tool for CRC patients. Our AI-driven pathological model TDAM-CRC provides a robust tool for improved CRC risk stratification, reveals new molecular targets, and facilitates personalized clinical decision-making.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>